NCT01620736: Trial to Assess Effect of Raltegravir on HTLV-1 Proviral Load |
|
|
| Withdrawn | 2 | 0 | NA | Raltegravir | Washington University School of Medicine, Merck Sharp & Dohme LLC | Human T-cell Leukemia Virus Type 1 Infection | 12/13 | 12/14 | | |
NCT01000285: EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma |
|
|
| Completed | 1/2 | 18 | US | Bortezomib, Velcade®, Etoposide, Toposar®, VePesid®, Etopophos®, Vincristine, Oncovin ®, Vincasar Pfs ®, Doxorubicin, Adriamycin ®, Rubex ®, Prednisone, Deltasone®, Liquid Pred®, Meticorten®, Orasone®, Cyclophosphamide, Cytoxan ®, Neosar ®, Raltegravir, Isentress® | Washington University School of Medicine | Leukemia-Lymphoma, Adult T-Cell | 05/14 | 04/16 | | |
